Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-R08b in Type III Gaucher's Disease
NCT07603050Phase 2Not yet recruiting
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, Small Molecules
01
Overview
A Phase 2 trial of VGN-R08b in Gaucher disease type 3, sponsored by Shanghai Vitalgen BioPharma Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
VGN-R08b
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT07603050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603050.